Groups that represent 340B hospitals yesterday slammed the multi-point 340B contract pharmacy policy that Bristol Myers Squibb (BMS) released last Friday.
Representatives of grantee covered entities, which BMS exempted from its contract pharmacy restrictions involving most of its products, overwhelmingly said solidarity with hospital covered entities remains as strong as ever. Privately, though, other grantee stakeholders said grantees are thinking about what they can do to make sure that manufacturers continue to let them use multiple contract pharmacies.
Groups that represent 340B hospitals yesterday slammed the multi-point 340B contract pharmacy policy that Bristol Meyers Squibb (BMS) released last Friday.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
